Anticancer metallopharmaceutical agents based on mixed-ligand palladium(II) complexes with dithiocarbamates and tertiary organophosphine ligands
作者:Hizbullah Khan、Amin Badshah、Muhammad Said、Ghulam Murtaza、Jamil Ahmad、Bertrand J. Jean-Claude、Margarita Todorova、Ian S. Butler
DOI:10.1002/aoc.2991
日期:2013.7
Mixed‐ligand palladium(II) complexes of the type [(DT)Pd(PR3)Cl], where DT = diethyldithiocarbamate (1), dibutyldithiocarbamate (2,3), dipropyldithiocarbamate (4,5), bis(2‐methoxyethyl)dithiocarbamate; PR3 = benzyldiphenylphosphine (1,4), diphenyl‐o‐tolylphosphine (2), diphenyl‐t‐butylphosphine (3), P‐chlorodiphenylphosphine (5) and triphenylphosphine (6), have been synthesized and characterized by
[(DT)Pd(PR 3)Cl]类型的混合配体钯(II)络合物,其中DT =二乙基二硫代氨基甲酸酯(1),二丁基二硫代氨基甲酸酯(2,3),二丙基二硫代氨基甲酸酯(4,5),双(2-甲氧基乙基) )二硫代氨基甲酸酯; PR 3 = benzyldiphenylphosphine(1,4),二苯基- Ô -tolylphosphine(2),二苯基-吨合成了丁基丁基膦(3),对氯二苯基膦(5)和三苯基膦(6)并通过元素分析和FT-IR,拉曼光谱和多核NMR光谱进行了表征。化合物1和2的结构是通过单晶X射线衍射(XRD)测量确定的,这些分析表明该络合物在Pd(II)周围具有伪正方形平面的几何形状,并且二硫代氨基甲酸酯配体结合在双齿中其余两个位置被有机叔膦和氯化物配体占据。抗癌研究表明,Pd(II)复合物对顺铂耐药的DU145人前列腺癌(HTB-81)细胞具有高活性,具有化合物6所示的最高活性(IC